| 1 |
Mechanisms of color formation in drug substance and mitigation strategies for the manufacture and storage of therapeutic proteins produced using mammalian cell culture
Du C, Xu JL, Song HT, Tao L, Lewandowski A, Ghose S, Borys MC, Li ZJ
Process Biochemistry, 86, 127, 2019 |
| 2 |
Effect of channel-induced shear on biologics during ultrafiltration/diafiltration (UF/DF)
Arunkumar A, Singh N, Schutsky EG, Peck M, Swanson RK, Borys MC, Li ZJ
Journal of Membrane Science, 514, 671, 2016 |
| 3 |
Size Reduction as Integral Element for Development and Manufacturing of Engineered Drug Particles
Juhnke M, John E
Chemical Engineering & Technology, 37(5), 757, 2014 |
| 4 |
Brown drug substance color investigation in cell culture manufacturing using chemically defined media: A case study
Xu JL, Jin M, Song HT, Huang C, Xu XK, Tian J, Qian NX, Steger K, Lewen NS, Tao L, Li ZJ
Process Biochemistry, 49(1), 130, 2014 |
| 5 |
Formulation and Manufacture of Pharmaceuticals by Fluidized-Bed Impregnation of Active Pharmaceutical Ingredients onto Porous Carriers
Grigorov PI, Glasser BJ, Muzzio FJ
AIChE Journal, 59(12), 4538, 2013 |
| 6 |
Protein and Solute Distribution in Drug Substance Containers During Frozen Storage and Post-Thawing: A Tool To Understand and Define Freezing-Thawing Parameters in Biotechnology Process Development
Kolhe P, Badkar A
Biotechnology Progress, 27(2), 494, 2011 |
| 7 |
Active utilization of solvent-mediated transformation for exclusive production of metastable polymorph crystals of AE1-923
Okamoto M, Hamano M, Ooshima H
Journal of Chemical Engineering of Japan, 37(1), 95, 2004 |
| 8 |
The effects of impurities on crystallization of polymorphs of a drug substance AE1-923
Okamoto M, Hamano M, Igarashi K, Ooshima H
Journal of Chemical Engineering of Japan, 37(10), 1224, 2004 |
